Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $11.43, for a total transaction of $22,860.00. Following the completion of the sale, the president now owns 2,893,138 shares in the company, valued at approximately $33,068,567.34. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Songjiang Ma also recently made the following trade(s):
- On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total value of $22,360.00.
- On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total value of $20,980.00.
- On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
- On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total transaction of $21,440.00.
- On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
- On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.10, for a total transaction of $565.60.
- On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
- On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total value of $9,560.56.
- On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total value of $24,800.00.
- On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total value of $25,000.00.
Gyre Therapeutics Trading Up 2.7 %
GYRE stock traded up $0.31 during trading hours on Tuesday, hitting $11.88. 38,939 shares of the stock traded hands, compared to its average volume of 96,847. The stock has a 50-day simple moving average of $11.09 and a 200 day simple moving average of $12.45. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $26.37.
Hedge Funds Weigh In On Gyre Therapeutics
Several hedge funds have recently made changes to their positions in the business. FMR LLC bought a new stake in Gyre Therapeutics during the third quarter worth approximately $47,000. Charles Schwab Investment Management Inc. lifted its position in shares of Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock valued at $1,425,000 after acquiring an additional 90,557 shares during the last quarter. State Street Corp grew its holdings in shares of Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after acquiring an additional 8,412 shares during the last quarter. Barclays PLC grew its holdings in shares of Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after acquiring an additional 6,855 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock worth $3,808,000 after purchasing an additional 43,840 shares during the period. Institutional investors and hedge funds own 23.99% of the company's stock.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
